怡达股份(300721.SZ):拟使用募资1253.40万元对珠海怡达仓储增资
格隆汇12月22日丨怡达股份(300721.SZ)公布,2020年12月21日,公司召开第三届董事会第二十三次会议审议通过了《关于使用募集资金对全资子公司增资的议案》。
此次公司将截至2020年12月21日剩余募集资金(包括公司利用暂时闲置募集资金进行现金管理取得的理财收益及募集资金专户活期利息收入)1253.40万元对全资子公司珠海怡达仓储有限公司(简称“珠海仓储”)进行增资。
珠海仓储注册资本将由9000万元增加至约1.03亿元,增资后仍为公司全资子公司。珠海仓储在获得上述增资后,将用于公司募投项目“3万立方液体化工品仓储项目”的实施,并对募集资金进行专户存储。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.